| BIOMARIN PHAR. DL-,001 |
| USA |
| Gesundheit |
| US09061G1013 / 924801 |
| BM8 (Frankfurt) / BMRN (NASDAQ) |
| FRA:BM8, ETR:BM8, BM8:GR, NASDAQ:BMRN |
| - |
| https://www.biomarin.com/ |
|
BioMarin Pharmaceutical Inc. is a leading global biotechnology company specializing in the development and commercialization of therapies for people with serious and life-threatening rare genetic diseases. Its portfolio includes eight approved treatm..
>Volltext.. |
| 8267.83 Mio. EUR |
| 7593.37 Mio. EUR |
| 2831.5 Mio. EUR |
| 698.02 Mio. EUR |
| 231.44 Mio. EUR |
| 1.2 EUR |
| 1245.51 Mio. EUR |
| 1913.95 Mio. EUR |
| - |
| 2.8 |
| 5.37% |
| -51.97% |
| - |
| - |
| - |
| BIOMARIN |
| 21.05.26 |
|